Genmab has two potential blockbusters up its sleeve
New drugs, which could boost Genmab’s earnings even further, are in the works at the biotech firm – but CEO Jan van de Winkel says the road to get there is long.
by astrid sturlason, translated by catherine brett
Genmab’s bestselling cancer drug Darzalex is still the firm’s crowning glory, but new income sources are also emerging.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Genmab cancer drug incomes surpass USD 400m in Q3
For subscribers
Analyst spots strong figures behind Genmab upgrade
For subscribers
